Cytomedix, Inc., a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies for wound and tissue repair, announced that the independent Data Safety Monitoring Board reviewing the safety data from the ongoing RECOVER-Stroke trial has recommended that the Phase 2 trial of ALD-401, a unique and differentiated stem cell population derived from patients' own bone marrow, can continue as designed.

Celsion Corporation, a leading oncology drug development company, today announced a joint resubmission with Philips Healthcare of an Investigational New Drug/Investigational Device Exemption application with the U.S. Food and Drug Administration for a Phase 2 clinical study of Celsion's ThermoDox® combined with Philips' Sonalleve® MR-HIFU technology for the treatment of prostate cancer metastases to the bone.

Bioanalytical Systems, Inc. today announced financial results for the second quarter and first half of fiscal 2012. "BASi's second quarter results are not indicative of the performance we expect from the company. We are taking a variety of actions on the revenue and cost sides of our business that are designed to position the company for future success, and we are confident that our operating results will improve as a result," said President and CEO Tony Chilton.

BioSyent Inc. is pleased to announce that its subsidiary BioSyent Pharma Inc. has launched Cathejellâ„¢ Jelly 2% a Sterile Topical Anesthetic for the Canadian healthcare market. Cathejellâ„¢ Jelly 2% is an innovative pharmaceutical product that combines a sterile gel and lidocaine in a unique collapsible applicator syringe which provides a safe and effective solution for patients to ease the discomfort of a range of medical procedures.

Verisante Technology, Inc., a leader in cancer detection technology, announced today that the Company has completed the design and fabrication of the beta version of Verisante Auraâ„¢. The units are intended for safety and field testing as a final step prior to the commencement of commercial production later this year.